FREE SHIPPING ON ORDERS OVER $300!
AOD 9604 + CJC-1295 + Ipamorelin 6/3/3 12mg

AOD-9604 + CJC-1295 + Ipamorelin

Blend ratio 6/3/3

Lyophilized powder · 12mg per vial · ≥99% purity (HPLC / MS)

AOD-9604 + CJC-1295 + Ipamorelin is a research peptide blend combining a synthetic fragment of human growth hormone with two growth hormone secretagogues. Studied for their effects on GH/IGF-1 axis signaling, lipolytic pathways, and somatotroph activity. For laboratory research use only — not for human consumption.

$120.00
  • ≥99% purity, HPLC / MS verified
  • Certificate of analysis on request
  • Made & shipped in the USA
  • Ships same business day if paid before 12PM PST (Mon–Fri)
  • Discreet, temperature-safe packaging with tracking
  • Free shipping on orders over $300

Specifications & Documentation

CompoundAOD
Strength12mg
FormLyophilized powder
Purity≥99% (HPLC / MS verified)
GradeResearch use only

This research blend combines three synthetic peptides — AOD-9604, CJC-1295, and Ipamorelin — in a single vial containing 12mg total (6mg AOD-9604, 3mg CJC-1295, 3mg Ipamorelin). Each peptide acts on a distinct pathway related to the growth hormone (GH) axis, making the combination a frequent subject of investigation in somatotropic and metabolic research models.

AOD-9604 is a modified synthetic fragment of the C-terminus of human growth hormone (hGH 177-191), with an additional tyrosine residue added to the N-terminus. Originally developed as a research candidate for lipolytic activity, it has been studied for its effects on lipid metabolism pathways that appear to operate independently of the GH receptor and IGF-1 signaling.

CJC-1295 (without DAC, in this blend) is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a tetra-substituted modification of GHRH 1-29. Research has examined its role as a GHRH receptor agonist that stimulates pulsatile GH release from pituitary somatotrophs, preserving the natural rhythm of GH secretion.

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue receptor (GHSR/ghrelin receptor) agonist. Studies have investigated its role in stimulating GH release through a pathway distinct from GHRH, with notable selectivity — minimal effect on cortisol, prolactin, or ACTH release compared to earlier secretagogues studied in the literature.

The combination is studied because the three peptides target complementary mechanisms: GHRH-receptor stimulation (CJC-1295), ghrelin-receptor stimulation (Ipamorelin), and a separate hGH-fragment lipolytic pathway (AOD-9604).

Research areas exploring this combination include:

  • Growth hormone secretion and pulsatility
  • GH/IGF-1 axis signaling
  • Somatotroph receptor pharmacology (GHRH-R and GHSR)
  • Lipolytic and lipid metabolism pathways
  • Body composition and metabolic regulation models
  • Comparative secretagogue activity and selectivity studies
  • Peptide synergy and combination pharmacology

Product Specifications

  • Peptides: AOD-9604 + CJC-1295 (no DAC) + Ipamorelin
  • Quantity: 6mg AOD-9604 + 3mg CJC-1295 + 3mg Ipamorelin (12mg total per vial)
  • AOD-9604: Modified hGH 177-191 fragment, 16 amino acids
  • CJC-1295 (no DAC): Modified GHRH 1-29 analog, 30 amino acids
  • Ipamorelin sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (pentapeptide)
  • Purity: ≥98% (HPLC verified)
  • Form: Lyophilized powder
  • Storage: Store at -20°C, protect from light and moisture; reconstituted solutions refrigerated

Disclaimer: This product is intended for laboratory and research purposes only. It is not a drug, food, or cosmetic, and is not intended for human or animal consumption, diagnostic use, or therapeutic application.